Skip to content
Screener

Arcutis Biotherapeutics, Inc. ARQT Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$1.7M+0.6%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$595K-21.2%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$2M-33.3%
PVL
Palvella TherapeuticsPVLA

Other financials

Income statement

See full
Revenue$129.9M+59.3%
Gross profit$118.9M+60.7%
Operating income$16.4M+212%
Net income$15.0M+194%
EPS (diluted)$0.11+185%

Balance sheet

See full
Cash & equivalents$34.4M-52.9%
Total debt$114.1M+3.6%
Total equity$220.6M+58.7%
Total assets$488.5M+38.6%

Cash flow

See full
Operating cash flow$12.6M
CapEx$158.0K+103%
Free cash flow$12.5M

Valuation

See full
Market cap$3.18B+86.8%
Enterprise value$3.26B+87.4%
P/S6.9×+0.4×

Profitability

See full
Gross margin91.1%+2.0pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.5×-0.3×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001787306-26-000051
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Stock-based compensation expense23,45220,267
Amortization of intangible assets1,1253,542
Non-cash interest expense941846
Net accretion on marketable securities(405)(1,554)
Other non-cash items, net491348
Changes in operating assets and liabilities:
Accounts receivable, net(8,934)(33,621)
Inventory(15,756)(1,433)

Item 1. Financial Statements (Unaudited)

FAQ

What is Arcutis Biotherapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
Arcutis Biotherapeutics, Inc. (ARQT) reported accretion (amortization) of discounts and premiums, investments of $223K in Q2 2026.
How has Arcutis Biotherapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
Arcutis Biotherapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 67.9% year-over-year, from $695K to $223K.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
Over 4 years (2021 to 2025), Arcutis Biotherapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a -11.6% compound annual growth rate (CAGR), from -$3.45M to $2.11M.
What does accretion (amortization) of discounts and premiums, investments mean?
Reflects the periodic adjustment to the carrying value of investment securities to reflect the amortization of premiums or the accretion of discounts over the life of the instrument. This non-cash adjustment reconciles the difference between the purchase price and the face value of debt securities held in the investment portfolio. It provides insight into the effective yield and interest income recognition of the company's treasury assets.

Ask your AI about Arcutis Biotherapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude